Emalex Biosciences receives FDA fast track designation for ecopipam for Tourette Syndrome

This article was originally published here

Fast Track designation is received when a potential new therapy is intended to treat a serious condition and data demonstrate the potential to address an unmet medical need.

The post Emalex Biosciences receives FDA fast track designation for ecopipam for Tourette Syndrome appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply